Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 26 entries
Sorted by: Best Match Show Resources per page
[In memoriam Prof. Albert Viethen, M.D].

Monatsschrift fur Kinderheilkunde

Windorfer A.
PMID: 366392
Monatsschr Kinderheilkd. 1978 Dec;126(12):726.

No abstract available.

Cite
Windorfer A. Professor Dr. Albert Viethen zum Gedächtnis. [In memoriam Prof. Albert Viethen, M.D]. Monatsschr Kinderheilkd. 1978;126(12):726
Windorfer, A. (1978). Professor Dr. Albert Viethen zum Gedächtnis. [In memoriam Prof. Albert Viethen, M.D]. Monatsschrift fur Kinderheilkunde, 126(12), 726.
Windorfer, A. "Professor Dr. Albert Viethen zum Gedächtnis." [In memoriam Prof. Albert Viethen, M.D]. Monatsschrift fur Kinderheilkunde vol. 126,12 (1978): 726.
Windorfer A. Professor Dr. Albert Viethen zum Gedächtnis. [In memoriam Prof. Albert Viethen, M.D]. Monatsschr Kinderheilkd. 1978 Dec;126(12):726. German. PMID: 366392.
Copy Download .nbib Format: NLM
[The changing nature of diseases of childhood].

Deutsche medizinische Wochenschrift (1946)

WINDORFER A.
PMID: 13473507
Dtsch Med Wochenschr. 1957 Sep 13;82(37):1596-9 contd. doi: 10.1055/s-0028-1116946.

No abstract available.

Cite
WINDORFER A. Vom Wandel der Krankheiten des Kindesalters. [The changing nature of diseases of childhood]. Dtsch Med Wochenschr. 1957;82(37):1596-9 contddoi: 10.1055/s-0028-1116946.
WINDORFER, A. (1957). Vom Wandel der Krankheiten des Kindesalters. [The changing nature of diseases of childhood]. Deutsche medizinische Wochenschrift (1946), 82(37), 1596-9 contd. https://doi.org/10.1055/s-0028-1116946
WINDORFER, A. "Vom Wandel der Krankheiten des Kindesalters." [The changing nature of diseases of childhood]. Deutsche medizinische Wochenschrift (1946) vol. 82,37 (1957): 1596-9 contd. doi: https://doi.org/10.1055/s-0028-1116946
WINDORFER A. Vom Wandel der Krankheiten des Kindesalters. [The changing nature of diseases of childhood]. Dtsch Med Wochenschr. 1957 Sep 13;82(37):1596-9 contd. doi: 10.1055/s-0028-1116946. German. PMID: 13473507.
Copy Download .nbib Format: NLM
On the spread of poliomyelitis in Germany.

Medizinische Klinik

WINDORFER A.
PMID: 18866347
Med Klin. 1948 Apr;43(7):245.

No abstract available.

Cite
WINDORFER A. Zur Ausbreitung der Poliomyelitis in Deutschland. On the spread of poliomyelitis in Germany. Med Klin. 1948;43(7):245
WINDORFER, A. (1948). Zur Ausbreitung der Poliomyelitis in Deutschland. On the spread of poliomyelitis in Germany. Medizinische Klinik, 43(7), 245.
WINDORFER, A. "Zur Ausbreitung der Poliomyelitis in Deutschland." On the spread of poliomyelitis in Germany. Medizinische Klinik vol. 43,7 (1948): 245.
WINDORFER A. Zur Ausbreitung der Poliomyelitis in Deutschland. On the spread of poliomyelitis in Germany. Med Klin. 1948 Apr;43(7):245. German. PMID: 18866347.
Copy Download .nbib Format: NLM
Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis.

United European gastroenterology journal

Jachs M, Binter T, Schmidbauer C, Hartl L, Strasser M, Laferl H, Hametner-Schreil S, Lindorfer A, Dax K, Stauber RE, Kessler HH, Bernhofer S, Maieron A, Loacker L, Bota S, Santonja I, Munda P, Mandorfer M, Peck-Radosavljevic M, Holzmann H, Gschwantler M, Zoller H, Ferenci P, Reiberger T.
PMID: 34873866
United European Gastroenterol J. 2021 Dec 07; doi: 10.1002/ueg2.12163. Epub 2021 Dec 07.

BACKGROUND: Hepatitis D virus (HDV) coinfection aggravates the course of hepatitis B virus (HBV). The prevalence of HDV in Austria is unknown.OBJECTIVE: This national study aimed at (i) recording the prevalence of HDV-infection in Austria and (ii) characterizing the...

Cite
Jachs M, Binter T, Schmidbauer C, et al. Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterol J. 2021;doi: 10.1002/ueg2.12163.
Jachs, M., Binter, T., Schmidbauer, C., Hartl, L., Strasser, M., Laferl, H., Hametner-Schreil, S., Lindorfer, A., Dax, K., Stauber, R. E., Kessler, H. H., Bernhofer, S., Maieron, A., Loacker, L., Bota, S., Santonja, I., Munda, P., Mandorfer, M., Peck-Radosavljevic, M., Holzmann, H., Gschwantler, M., Zoller, H., Ferenci, P., & Reiberger, T. (2021). Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European gastroenterology journal, . https://doi.org/10.1002/ueg2.12163
Jachs, Mathias, et al. "Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis." United European gastroenterology journal vol. (2021). doi: https://doi.org/10.1002/ueg2.12163
Jachs M, Binter T, Schmidbauer C, Hartl L, Strasser M, Laferl H, Hametner-Schreil S, Lindorfer A, Dax K, Stauber RE, Kessler HH, Bernhofer S, Maieron A, Loacker L, Bota S, Santonja I, Munda P, Mandorfer M, Peck-Radosavljevic M, Holzmann H, Gschwantler M, Zoller H, Ferenci P, Reiberger T. Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterol J. 2021 Dec 07; doi: 10.1002/ueg2.12163. Epub 2021 Dec 07. PMID: 34873866.
Copy Download .nbib Format: NLM
Corrigendum: IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.

Nature immunology

Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, Kang TH, Tanno H, Delidakis G, Alford C, Taylor RP, Nimmerjahn F, Varadarajan N, Bruhns P, Zhang YJ, Georgiou G.
PMID: 28926542
Nat Immunol. 2017 Sep 19;18(10):1173. doi: 10.1038/ni1017-1173c.

No abstract available.

Cite
Lee CH, Romain G, Yan W, et al. Corrigendum: IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions. Nat Immunol. 2017;18(10):1173doi: 10.1038/ni1017-1173c.
Lee, C. H., Romain, G., Yan, W., Watanabe, M., Charab, W., Todorova, B., Lee, J., Triplett, K., Donkor, M., Lungu, O. I., Lux, A., Marshall, N., Lindorfer, M. A., Goff, O. R., Balbino, B., Kang, T. H., Tanno, H., Delidakis, G., Alford, C., Taylor, R. P., Nimmerjahn, F., Varadarajan, N., Bruhns, P., Zhang, Y. J., & Georgiou, G. (2017). Corrigendum: IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions. Nature immunology, 18(10), 1173. https://doi.org/10.1038/ni1017-1173c
Lee, Chang-Han, et al. "Corrigendum: IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions." Nature immunology vol. 18,10 (2017): 1173. doi: https://doi.org/10.1038/ni1017-1173c
Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, Kang TH, Tanno H, Delidakis G, Alford C, Taylor RP, Nimmerjahn F, Varadarajan N, Bruhns P, Zhang YJ, Georgiou G. Corrigendum: IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions. Nat Immunol. 2017 Sep 19;18(10):1173. doi: 10.1038/ni1017-1173c. PMID: 28926542.
Copy Download .nbib Format: NLM
Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis.

United European gastroenterology journal

Jachs M, Binter T, Schmidbauer C, Hartl L, Strasser M, Laferl H, Hametner-Schreil S, Lindorfer A, Dax K, Stauber RE, Kessler HH, Bernhofer S, Maieron A, Loacker L, Bota S, Santonja I, Munda P, Mandorfer M, Peck-Radosavljevic M, Holzmann H, Gschwantler M, Zoller H, Ferenci P, Reiberger T.
PMID: 34873866
United European Gastroenterol J. 2021 Dec;9(10):1119-1127. doi: 10.1002/ueg2.12163. Epub 2021 Dec 07.

BACKGROUND: Hepatitis D virus (HDV) coinfection aggravates the course of hepatitis B virus (HBV). The prevalence of HDV in Austria is unknown.OBJECTIVE: This national study aimed at (i) recording the prevalence of HDV-infection in Austria and (ii) characterizing the...

Cite
Jachs M, Binter T, Schmidbauer C, et al. Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterol J. 2021;9(10):1119-1127doi: 10.1002/ueg2.12163.
Jachs, M., Binter, T., Schmidbauer, C., Hartl, L., Strasser, M., Laferl, H., Hametner-Schreil, S., Lindorfer, A., Dax, K., Stauber, R. E., Kessler, H. H., Bernhofer, S., Maieron, A., Loacker, L., Bota, S., Santonja, I., Munda, P., Mandorfer, M., Peck-Radosavljevic, M., Holzmann, H., Gschwantler, M., Zoller, H., Ferenci, P., & Reiberger, T. (2021). Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European gastroenterology journal, 9(10), 1119-1127. https://doi.org/10.1002/ueg2.12163
Jachs, Mathias, et al. "Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis." United European gastroenterology journal vol. 9,10 (2021): 1119-1127. doi: https://doi.org/10.1002/ueg2.12163
Jachs M, Binter T, Schmidbauer C, Hartl L, Strasser M, Laferl H, Hametner-Schreil S, Lindorfer A, Dax K, Stauber RE, Kessler HH, Bernhofer S, Maieron A, Loacker L, Bota S, Santonja I, Munda P, Mandorfer M, Peck-Radosavljevic M, Holzmann H, Gschwantler M, Zoller H, Ferenci P, Reiberger T. Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterol J. 2021 Dec;9(10):1119-1127. doi: 10.1002/ueg2.12163. Epub 2021 Dec 07. PMID: 34873866; PMCID: PMC8672089.
Copy Download .nbib Format: NLM
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.

Genome medicine

Vangala D, Ladigan S, Liffers ST, Noseir S, Maghnouj A, Götze TM, Verdoodt B, Klein-Scory S, Godfrey L, Zowada MK, Huerta M, Edelstein DL, de Villarreal JM, Marqués M, Kumbrink J, Jung A, Schiergens T, Werner J, Heinemann V, Stintzing S, Lindoerfer D, Mansmann U, Pohl M, Teschendorf C, Bernhardt C, Wolters H, Stern J, Usta S, Viebahn R, Admard J, Casadei N, Fröhling S, Ball CR, Siveke JT, Glimm H, Tannapfel A, Schmiegel W, Hahn SA.
PMID: 34271981
Genome Med. 2021 Jul 16;13(1):116. doi: 10.1186/s13073-021-00926-7.

BACKGROUND: The development of secondary resistance (SR) in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (anti-EGFR) antibodies is not fully understood at the molecular level. Here we tested in vivo selection of anti-EGFR SR tumors in...

Cite
Vangala D, Ladigan S, Liffers ST, et al. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Med. 2021;13(1):116doi: 10.1186/s13073-021-00926-7.
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T. M., Verdoodt, B., Klein-Scory, S., Godfrey, L., Zowada, M. K., Huerta, M., Edelstein, D. L., de Villarreal, J. M., Marqués, M., Kumbrink, J., Jung, A., Schiergens, T., Werner, J., Heinemann, V., Stintzing, S., Lindoerfer, D., Mansmann, U., Pohl, M., Teschendorf, C., Bernhardt, C., Wolters, H., Stern, J., Usta, S., Viebahn, R., Admard, J., Casadei, N., Fröhling, S., Ball, C. R., Siveke, J. T., Glimm, H., Tannapfel, A., Schmiegel, W., & Hahn, S. A. (2021). Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome medicine, 13(1), 116. https://doi.org/10.1186/s13073-021-00926-7
Vangala, Deepak, et al. "Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models." Genome medicine vol. 13,1 (2021): 116. doi: https://doi.org/10.1186/s13073-021-00926-7
Vangala D, Ladigan S, Liffers ST, Noseir S, Maghnouj A, Götze TM, Verdoodt B, Klein-Scory S, Godfrey L, Zowada MK, Huerta M, Edelstein DL, de Villarreal JM, Marqués M, Kumbrink J, Jung A, Schiergens T, Werner J, Heinemann V, Stintzing S, Lindoerfer D, Mansmann U, Pohl M, Teschendorf C, Bernhardt C, Wolters H, Stern J, Usta S, Viebahn R, Admard J, Casadei N, Fröhling S, Ball CR, Siveke JT, Glimm H, Tannapfel A, Schmiegel W, Hahn SA. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Med. 2021 Jul 16;13(1):116. doi: 10.1186/s13073-021-00926-7. PMID: 34271981; PMCID: PMC8283888.
Copy Download .nbib Format: NLM
[51st Meeting of the German Society of Pediatrics, Heidelberg, Aug 26-29, 1951].

Deutsche medizinische Wochenschrift (1946)

WINDORFER A.
PMID: 14916587
Dtsch Med Wochenschr. 1951 Dec 07;76(49):1572-3.

No abstract available.

Cite
WINDORFER A. Einundfünfzigste Tagung der Deutschen Gesellschaft für Kinderheilkunde vom 26. bis 29. August 1951 in Heidelberg. [51st Meeting of the German Society of Pediatrics, Heidelberg, Aug 26-29, 1951]. Dtsch Med Wochenschr. 1951;76(49):1572-3
WINDORFER, A. (1951). Einundfünfzigste Tagung der Deutschen Gesellschaft für Kinderheilkunde vom 26. bis 29. August 1951 in Heidelberg. [51st Meeting of the German Society of Pediatrics, Heidelberg, Aug 26-29, 1951]. Deutsche medizinische Wochenschrift (1946), 76(49), 1572-3.
WINDORFER, A. "Einundfünfzigste Tagung der Deutschen Gesellschaft für Kinderheilkunde vom 26. bis 29. August 1951 in Heidelberg." [51st Meeting of the German Society of Pediatrics, Heidelberg, Aug 26-29, 1951]. Deutsche medizinische Wochenschrift (1946) vol. 76,49 (1951): 1572-3.
WINDORFER A. Einundfünfzigste Tagung der Deutschen Gesellschaft für Kinderheilkunde vom 26. bis 29. August 1951 in Heidelberg. [51st Meeting of the German Society of Pediatrics, Heidelberg, Aug 26-29, 1951]. Dtsch Med Wochenschr. 1951 Dec 07;76(49):1572-3. German. PMID: 14916587.
Copy Download .nbib Format: NLM
Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis.

United European gastroenterology journal

Jachs M, Binter T, Schmidbauer C, Hartl L, Strasser M, Laferl H, Hametner-Schreil S, Lindorfer A, Dax K, Stauber RE, Kessler HH, Bernhofer S, Maieron A, Loacker L, Bota S, Santonja I, Munda P, Mandorfer M, Peck-Radosavljevic M, Holzmann H, Gschwantler M, Zoller H, Ferenci P, Reiberger T.
PMID: 34873866
United European Gastroenterol J. 2021 Dec;9(10):1119-1127. doi: 10.1002/ueg2.12163. Epub 2021 Dec 07.

BACKGROUND: Hepatitis D virus (HDV) coinfection aggravates the course of hepatitis B virus (HBV). The prevalence of HDV in Austria is unknown.OBJECTIVE: This national study aimed at (i) recording the prevalence of HDV-infection in Austria and (ii) characterizing the...

Cite
Jachs M, Binter T, Schmidbauer C, et al. Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterol J. 2021;9(10):1119-1127doi: 10.1002/ueg2.12163.
Jachs, M., Binter, T., Schmidbauer, C., Hartl, L., Strasser, M., Laferl, H., Hametner-Schreil, S., Lindorfer, A., Dax, K., Stauber, R. E., Kessler, H. H., Bernhofer, S., Maieron, A., Loacker, L., Bota, S., Santonja, I., Munda, P., Mandorfer, M., Peck-Radosavljevic, M., Holzmann, H., Gschwantler, M., Zoller, H., Ferenci, P., & Reiberger, T. (2021). Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European gastroenterology journal, 9(10), 1119-1127. https://doi.org/10.1002/ueg2.12163
Jachs, Mathias, et al. "Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis." United European gastroenterology journal vol. 9,10 (2021): 1119-1127. doi: https://doi.org/10.1002/ueg2.12163
Jachs M, Binter T, Schmidbauer C, Hartl L, Strasser M, Laferl H, Hametner-Schreil S, Lindorfer A, Dax K, Stauber RE, Kessler HH, Bernhofer S, Maieron A, Loacker L, Bota S, Santonja I, Munda P, Mandorfer M, Peck-Radosavljevic M, Holzmann H, Gschwantler M, Zoller H, Ferenci P, Reiberger T. Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterol J. 2021 Dec;9(10):1119-1127. doi: 10.1002/ueg2.12163. Epub 2021 Dec 07. PMID: 34873866.
Copy Download .nbib Format: NLM
[The early diagnosis of poliomyelitis].

Medizinische Klinik

WINDORFER A, SCHLANSTEDT R.
PMID: 13845194
Med Klin. 1959 Sep 04;54:1607-10.

No abstract available.

Cite
WINDORFER A, SCHLANSTEDT R. [The early diagnosis of poliomyelitis]. Med Klin. 1959;54:1607-10
WINDORFER, A., & SCHLANSTEDT, R. (1959). [The early diagnosis of poliomyelitis]. Medizinische Klinik, 541607-10.
WINDORFER, A, and SCHLANSTEDT, R. "[The early diagnosis of poliomyelitis]." Medizinische Klinik vol. 54 (1959): 1607-10.
WINDORFER A, SCHLANSTEDT R. [The early diagnosis of poliomyelitis]. Med Klin. 1959 Sep 04;54:1607-10. German. PMID: 13845194.
Copy Download .nbib Format: NLM
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?.

Oncoimmunology

Lindorfer MA, Wiestner A, Zent CS, Taylor RP.
PMID: 23162771
Oncoimmunology. 2012 Sep 01;1(6):959-961. doi: 10.4161/onci.20368.

Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the...

Cite
Lindorfer MA, Wiestner A, Zent CS, et al. Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?. Oncoimmunology. 2012;1(6):959-961doi: 10.4161/onci.20368.
Lindorfer, M. A., Wiestner, A., Zent, C. S., & Taylor, R. P. (2012). Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?. Oncoimmunology, 1(6), 959-961. https://doi.org/10.4161/onci.20368
Lindorfer, Margaret A, et al. "Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?." Oncoimmunology vol. 1,6 (2012): 959-961. doi: https://doi.org/10.4161/onci.20368
Lindorfer MA, Wiestner A, Zent CS, Taylor RP. Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?. Oncoimmunology. 2012 Sep 01;1(6):959-961. doi: 10.4161/onci.20368. PMID: 23162771; PMCID: PMC3489759.
Copy Download .nbib Format: NLM
Kinetic and kinematic differences between deadlifts and goodmornings.

BMC sports science, medicine & rehabilitation

Schellenberg F, Lindorfer J, List R, Taylor WR, Lorenzetti S.
PMID: 24314057
BMC Sports Sci Med Rehabil. 2013 Dec 07;5(1):27. doi: 10.1186/2052-1847-5-27.

BACKGROUND: In order to improve training performance, as well as avoid overloading during prevention and rehabilitation exercises in patients, the aim of this study was to understand the biomechanical differences in the knee, hip and the back between the...

Cite
Schellenberg F, Lindorfer J, List R, et al. Kinetic and kinematic differences between deadlifts and goodmornings. BMC Sports Sci Med Rehabil. 2013;5(1):27doi: 10.1186/2052-1847-5-27.
Schellenberg, F., Lindorfer, J., List, R., Taylor, W. R., & Lorenzetti, S. (2013). Kinetic and kinematic differences between deadlifts and goodmornings. BMC sports science, medicine & rehabilitation, 5(1), 27. https://doi.org/10.1186/2052-1847-5-27
Schellenberg, Florian, et al. "Kinetic and kinematic differences between deadlifts and goodmornings." BMC sports science, medicine & rehabilitation vol. 5,1 (2013): 27. doi: https://doi.org/10.1186/2052-1847-5-27
Schellenberg F, Lindorfer J, List R, Taylor WR, Lorenzetti S. Kinetic and kinematic differences between deadlifts and goodmornings. BMC Sports Sci Med Rehabil. 2013 Dec 07;5(1):27. doi: 10.1186/2052-1847-5-27. PMID: 24314057; PMCID: PMC3878967.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 26 entries